Axovant to Present at 36th Annual J.P. Morgan Healthcare Conference

BASEL, Switzerland, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXON) today announced that its Chief Executive Officer David Hung, MD, will be presenting at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9^th at 10:00 a.m. PST at the Westin St. Francis Hotel in San Francisco. In addition, he will participate in a break-out session immediately following the presentation.

A simultaneous webcast will be available in the “Investors” section of the Company’s website at http://investors.axovant.com. A replay of the webcast will be available for 30 days following the live event.

About Axovant Sciences
Axovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines to broadly address multiple forms of dementia and related neurological disorders. Axovant is developing a pipeline of product candidates that focuses on the cognitive, functional and behavioral aspects of debilitating conditions such as Alzheimer's disease, Lewy body dementia and other neurological disorders. For more information, visit www.axovant.com.

Contacts:
Investors & Media   
Samina Bari   
Vice President, Corporate Affairs
[email protected] 
[email protected] 

Media
Brian Reid
W2O Group
[email protected] 
402.875.0525

You May Also Be Interested In

• Axon raises $1.15B through convertible notes due 2031
• Alvarez & Marsal Expands Commercial Due Diligence Practice with Three Senior Appointments to Meet Growing Client Demand
• Avangrid Surpasses 500 MW of Power Infrastructure Installed or Energized in 2026